经尿道二次电切在pT<sub>1</sub>期非肌层浸润性膀胱癌的预后价值研究

doi:10.3877/cma.j.issn.1674-3253.2022.04.007

目的

评估常规二次经尿道膀胱肿瘤切除术（STURBT）对初诊T₁期非肌层浸润性膀胱癌（NMIBC）患者远期预后的价值。

方法

本研究回顾性分析了在我院接受治疗的256例pT₁期NMIBC患者，接受经尿道膀胱肿瘤电切术（TURBT）患者126例，接受二次TURBT（STURBT）的患者130例。通过查阅病历资料和随访的方式评估两种手术方式的预后疗效。我们记录了两组患者疾病复发及死亡情况。最后，总的疾病复发率（DRR）、疾病特异性死亡率（DSM）及2年、4年和6年无复发生存率（RFS）和总生存率（OS）作为两组对比分析指标。

结果

两组患者随访时间为6年，相比较TURBT组，STURBT组的DRR（42.1% vs 61.9%，P=0.001）和DSM（23.1% vs 35.7%，P=0.026）均显著降低；4年和6年的RFS（59.2% vs 44.4%，P=0.018；55.4% vs 38.1%，P=0.006）明显升高；6年OS（76.2% vs 64.3%，P=0.038）也明显升高。利用Kaplan-Meier法构建的RFS、OS曲线显现出差异有统计学意义（RFS：P=0.001；OS：P=0.029），STURBT组RFS、OS均优于TURBT组。

结论

pT₁期NMIBC患者STURBT的预后价值，不仅对患者RFS有利，而且对长期OS有利。

关键词: 膀胱癌, 二次电切, 生存率, 预后

Objective

To evaluate the effect of routine second transurethral cystectomy (STURBT) on the long-term prognosis of newly diagnosed pT₁ non-muscular invasive bladder cancer (NMIBC).

Methods

This study retrospectively analyzed 256 patients with T₁ stage NMIBC who received treatment in our hospital, including 126 patients who received TURBT and 130 patients who received STURBT. The prognosis of the two surgical methods was evaluated by medical records and following up. Recurrence and death were recorded in both groups. Finally, the total rate of disease recurrence (DRR), disease-specific mortality (DSM), 2-year, 4-year and 6-year recurrence free survival (RFS) and overall survival (OS) were compared and analyzed as indicators of the two groups.

Results

The follow-up time of the two groups was 6 years, and the DRR (42.1% vs 61.9%, P=0.001) and DSM (23.1 vs 35.7%, P=0.026) of the STURBT group were significantly reduced compared with TURBT group. 4-year and 6-year RFS (59.2% vs 44.4%, P=0.018; 55.4% vs 38.1%, P=0.006) significantly increased; 6-year OS (76.2 % vs 64.3%, P=0.038) was also significantly higher. The RFS and OS curves constructed by Kaplan-Meier method showed statistical difference (RFS: P=0.001; OS: P=0.029), RFS and OS in STURBT group were superior to those in TURBT group.

Conclusion

The prognostic value of STURBT in pT₁ NMIBC patients was not only beneficial to patients' RFS, but also to patients' long-term OS.

Key words: Bladder cancer, Secondary electrotomy, Overall survival, Prognosis

图1 非肌层浸润性膀胱癌患者入组研究流程图

图2 非肌层浸润性膀胱癌患者无复发生存率和总生存率的Kaplan-Meier曲线

表1 两组患者的人口统计学数据和基线肿瘤特征

组别	例数	年龄(岁)	性别(例)		肿瘤大小(例)				肿瘤分级(例)
			男	女	单发		多发		低	高
			男	女	<3 cm	≥3 cm	<3 cm	≥3 cm	低	高
TURBT组	126	64±19	110	16	29	12	52	33	69	57
STURBT组	130	64±17	112	18	32	11	49	38	67	63
统计值		t=0.457	χ²=0.073		χ²=0.143		χ²=0.418		χ²=0.267
P值		0.638	0.787		0.705		0.518		0.605

表1 两组患者的人口统计学数据和基线肿瘤特征

组别	例数	年龄(岁)	性别(例)		肿瘤大小(例)				肿瘤分级(例)
			男	女	单发		多发		低	高
			男	女	<3 cm	≥3 cm	<3 cm	≥3 cm	低	高
TURBT组	126	64±19	110	16	29	12	52	33	69	57
STURBT组	130	64±17	112	18	32	11	49	38	67	63
统计值		t=0.457	χ²=0.073		χ²=0.143		χ²=0.418		χ²=0.267
P值		0.638	0.787		0.705		0.518		0.605

表2 研究组的预后和生存参数

组别	例数	复发[例(%)]	疾病特异性死亡[例(%)]	无复发生存率(%)			总生存率(%)
组别	例数	复发[例(%)]	疾病特异性死亡[例(%)]	2年	4年	6年	2年	4年	6年
TURBT组	126	78（61.9）	45（35.7）	53.2	44.4	38.1	90.5	77.0	64.3
STURBT组	130	53（42.1）	30（23.1）	64.6	59.2	55.4	90.8	80.8	76.2
χ²值		11.439	4.933	3.462	5.604	7.681	0.006	0.551	4.318
P值		0.001	0.026	0.063	0.018	0.006	0.936	0.458	0.038

表2 研究组的预后和生存参数

组别	例数	复发[例(%)]	疾病特异性死亡[例(%)]	无复发生存率(%)			总生存率(%)
组别	例数	复发[例(%)]	疾病特异性死亡[例(%)]	2年	4年	6年	2年	4年	6年
TURBT组	126	78（61.9）	45（35.7）	53.2	44.4	38.1	90.5	77.0	64.3
STURBT组	130	53（42.1）	30（23.1）	64.6	59.2	55.4	90.8	80.8	76.2
χ²值		11.439	4.933	3.462	5.604	7.681	0.006	0.551	4.318
P值		0.001	0.026	0.063	0.018	0.006	0.936	0.458	0.038

[1]	Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016 [J]. Eur Urol, 2017, 71(3): 447-461.
[2]	Torre LA, BRAY F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA: a Cancer J Clin, 2015, 65(2): 87-108.
[3]	Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer[J]. Urol Clin North Am, 1992, 19(3): 435-453.
[4]	黄健，郭应禄，那彦群, 等. 中国泌尿外科和男科疾病诊断治疗指南手册: 2019版[M]. 科学出版社, 2019.
[5]	Shen Z, Xie L, Chen T, et al. Risk factors predictive of recurrence and progression for patients who suffered initial recurrence after transurethral resection of stage pt1 bladder tumor in chinese population: a retrospective study [J]. Medicine, 2016, 95(5): e2625.
[6]	Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial [J]. Eur Urol, 2010, 58(2): 185-190.
[7]	Divrik T, Yildirim U, Eroğlu AS, et al. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? [J]. J Urol, 2006, 175(4): 1258-1261.
[8]	Rigaud J, Karam G, Braud G, et al. T1 bladder tumors: value of a second endoscopic resection] [J]. Prog Urol，2002, 12(1): 27-30.
[9]	Zurkirchen MA, Sulser T, Gaspert A, et al. Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists [J]. Urol Int, 2004, 72(2): 99-102.
[10]	Vögeli TA, Grimm MO, Simon X, et al. Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma[J]. Der Urologe Ausg A, 2002, 41(5): 470-440.
[11]	Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?[J]. Urology, 2002, 59(2): 220-223.
[12]	Jakse G, Algaba F, Malmström PU, et al. A second-look TUR in T1 transitional cell carcinoma: why? [J]. Eur Urol, 2004, 45(5): 539-546.
[13]	Engilbertsson H, Aaltonen KE, Björnsson S, et al. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream[J]. J Urol, 2015, 193(1): 53-57.
[14]	Divrik RT, Yildirim U, Zorlu F, et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial[J]. J Urol, 2006, 175(5): 1641-1644.
[15]	Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review [J]. Eur Urol, 2018, 73(6): 925-933.
[16]	Kim W, Song C, Park S, et al. Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor [J]. J Endourol, 2012, 26(8): 1059-1064.
[17]	Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy [J]. J Urol, 2005, 174(6): 2134-2137.

[1]	衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2]	施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[3]	谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[4]	马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[5]	杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[6]	栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[7]	顾志波, 郝林, 陆明, 陈建刚. 光动力纳米载体联合si-P3H4治疗膀胱癌的初步探索[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 633-641.
[8]	姜明, 罗锐, 龙成超. 闭孔疝的诊断与治疗：10年73例患者诊疗经验总结[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 706-710.
[9]	钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[10]	胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[11]	陆萍, 邹健. 凝血和纤维蛋白溶解标志物的动态变化对急性胰腺炎患者预后的评估价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 427-432.
[12]	李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[13]	王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[14]	索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
[15]	邓世栋, 刘凌志, 郭大勇, 王超, 黄忠欣, 张晖辉. 沉默SNHG1基因对膀胱癌细胞增殖、凋亡、迁移和铁死亡的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 804-811.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic value of transurethral secondary electrotomy in pT₁ stage non-muscular invasive bladder cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Prognostic value of transurethral secondary electrotomy in pT1 stage non-muscular invasive bladder cancer

Prognostic value of transurethral secondary electrotomy in pT₁ stage non-muscular invasive bladder cancer